Printer Friendly

Kirin to expand capacity in Japan.

Kirin Brewery Co. plans to spend more than 35 billion yen by the end of next year to expand capacity in an effort to improve productivity, a spokesman said.

At a time when the economy has been sluggish, Japanese companies in general have been curtailing investment in plant and equipment, but Kirin has been making hefty outlays on plant and equipment to modernize factories in expectation of steady growth in demand for beer.

The brewer has detailed its nine-year overhaul plan for a plant in Nagoya. The plant will expand capacity to 340,000 kilo-liters a year by 1994 from the current 290,000 kilo-liters, at a total cost of 35.30 billion yen. The plan also calls for further increase of capacity to 360,000 kilo-liters by 1996. In addition, Kirin will spend roughly 8 billion yen to build a distribution center near its plant in Yokohama.
COPYRIGHT 1993 Business Journals, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Kirin Brewery Company Ltd.
Publication:Modern Brewery Age
Date:Jul 19, 1993
Previous Article:Coors announces white-collar job cuts.
Next Article:Anheuser-Busch stock lackluster, analysts say.

Related Articles
Anheuser-Busch and Kirin form alliance for Japanese Budweiser production.
Kirin selects Willow as "best sales partner." (Kirin Brewery Company Ltd.; Willow Distributors Inc.)
Kirin intros brands to recapture Japan mkt. share.
Kirin to cut brewery staff by twenty percent.
Asahi on a roll in Japan, posting record net profit in 2001.
Kirin begins selling "shochu" distilled spirit. (Marketplace).
Kirin in Licensing Agreement with Anheuser-Busch for US Market.
Kirin Group and Yakult Group to Establish Kirin Yakult NextStage as Part of Alliance.
Kirin Group, Yakult establish Kirin Yakult NextStage.
Kirin and Astellas Enter Into Licensing Agreement on Immunosuppressive Fully Human Monoclonal Antibody.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters